Fidelity leads $100m Series C round in China-based clinical CRO dMed

Fidelity leads $100m Series C round in China-based clinical CRO dMed

Source: Volodymyr Hryshchenko/Unsplash

17 December, 2020

CRO dMed Biopharmaceutical Fidelity Management & Research Company

Printed by Unregistered user on Sun, 28 Dec 2025 03:14:13 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Venture Capital

Fidelity leads $97m Series C round in Chinese biopharma Antengene

Asia PE-VC Summit 2020

How VCs are straddling cross-border investments in India, SE Asia

Read more from Greater China

Policy & Regulations

China issues draft rules to govern AI with human-like interaction

China eases IPO rules for firms developing reusable rockets